Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3922 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Transition’s hepatitis drug shows potential

The product, HCV-IET, combines Transition’s interferon enhancer, EMZ702, with the current standard of care for hepatitis C, a combination therapy of pegylated interferon alpha and ribavirin. The study

Eisai sues to protect Aricept

Eisai said that it believes that its patent covering the composition of donepezil, the active ingredient in Aricept, is valid until its expiration date of November 25, 2010,

Amorfix and Biogen Idec form ALS collaboration

As part of the agreement, Biogen Idec has acquired an option to the exclusive worldwide rights to develop and commercialize therapeutics for the treatment of amyotrophic lateral sclerosis